

## First-line Chemotherapy With or Without Tislelizumab for Extensive-stage Small Cell Lung Cancer: RATIONALE-312 Phase 3 Study

Ying Cheng,<sup>1</sup>\* Yun Fan,<sup>2</sup> Yanqiu Zhao,<sup>3</sup> Dingzhi Huang,<sup>4</sup> Xingya Li,<sup>5</sup> Peng Zhang,<sup>6</sup> Mafei Kang,<sup>7</sup> Nong Yang,<sup>8</sup> Diansheng Zhong,<sup>9</sup> Zhen Wang,<sup>10</sup> Yan Yu,<sup>11</sup> Yu Zhang,<sup>12</sup> Jun Zhao,<sup>13</sup> Tai Qin,<sup>14</sup> Chenqi Chen,<sup>15</sup> Shiangjiin Leaw,<sup>15</sup> Wenjuan Zheng,<sup>14</sup> and Yong Song,<sup>16</sup> on behalf of the RATIONALE-312 Study Group

<sup>1</sup>Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China; <sup>2</sup>Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China; <sup>3</sup>Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China; <sup>4</sup>Pulmonary Oncology Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; <sup>5</sup>Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou, China; <sup>6</sup>Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; <sup>7</sup>Department of Medical Oncology, The Affiliated Hospital of Guilin Medical University, Guilin, China; <sup>8</sup>Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China; <sup>9</sup>Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China; <sup>10</sup>Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; <sup>11</sup>Harbin Medical University Cancer Hospital, Harbin, China; <sup>12</sup>Department of Respiratory Medicine, Nanjing Chest Hospital, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, China; <sup>13</sup>Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, China; <sup>14</sup>BeiGene (Beijing) Co., Ltd., Beijing, China; <sup>15</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, China; <sup>16</sup>Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, China. <sup>\*</sup>Presenting author

> Please use this link to view a **PLS of the abstract**: <u>https://protect-eu.mimecast.com/s/VCdBCzVZuMO31Qku4dxhY?domain=epg-digital.com</u> **Note:** Copies of this PLS obtained through this link are for personal use only and may not be reproduced without written permission of the authors.





## Background

- The prognosis for ES-SCLC is exceptionally poor, with limited treatment options<sup>1-3</sup>
- Platinum-based chemotherapy (etoposide plus platinum) has been the standard of care for three decades<sup>3,4</sup>
- Anti-PD-L1 antibodies in combination with chemotherapy have emerged as the new standard of care for 1L ES-SCLC in recent years<sup>5-7</sup>; however, the flexibility to select a treatment regimen based on efficacy, safety, and accessibility in clinical practice is still limited
- Tislelizumab, a monoclonal antibody with high affinity and binding specificity for PD-1,<sup>8</sup> in combination with chemotherapy showed promising antitumor activity in patients with untreated ES-SCLC in a phase 2 study<sup>9</sup>
- The phase 3 RATIONALE-312 trial aimed to compare the efficacy and safety of tislelizumab versus placebo in combination with etoposide plus platinum as 1L treatment for patients with ES-SCLC in China


1. Rudin CM, et al. Nat Rev Dis Primers. 2021;7:3; 2. Oronsky B, et al. J Cancer. 2022;13:2945-2953; 3. Sathiyapalan A, et al. Curr Oncol. 2022;29:9046-9065; 4. Paz-Ares L, et al. Lancet. 2019;394:1929-1939; 5. Paz-Ares L, et al. ESMO Open. 2022:7:100408; 6. Liu SV, et al. J Clin Oncol. 2021;39:619-630; 7. Mathieu L, et al. Oncologist. 2021;26:433-438; 8. Hong Y, et al. FEBS Open Bio. 2021;11:782-792; 9. Wang Z, et al. Lung Cancer. 2020;147:259-268. Abbreviations: 1L, first-line; ES-SCLC, extensive-stage small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.





## Study Design

Randomized, double-blind, placebo-controlled, multicenter, phase 3 study (NCT04005716)



#### **Stratification factors**

- ECOG PS (0 vs 1)
- Cisplatin vs carboplatin
- Brain metastasis (yes vs no)

#### Primary endpoint: OS Key secondary endpoints:

- PFS, ORR, and DoR (INV-assessed)
- (INV-assessed)
- Safety and tolerability

#### **Statistical methods**


- Planned to enroll 455 pts; 80% power to detect HR 0.74 with 353 OS events
- Hierarchical testing on PFS: only when OS demonstrates significance<sup>a</sup>



Abbreviations: AUC, area under the curve; D, day; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; ES-SCLC, extensive-stage small cell lung cancer; HR, hazard ratio; INV, investigator; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; Q3W, every 3 weeks; R, randomized.



## Patient Disposition



Abbreviation: chemo, chemotherapy





## **Baseline Characteristics**


		Tislelizumab + chemo (n=227)	Placebo + chemo (n=230)
Age (years), median (range)		63 (31-78)	62 (34-78)
≥65 years, n (%)		89 (39.2)	81 (35.2)
Male, n (%)		186 (81.9)	186 (80.9)
ECOG PS, n (%)	0 1	35 (15.4) 192 (84.6)	34 (14.8) 196 (85.2)
Smoking status, n (%)	Never	53 (23.3)	59 (25.7)
	Current	151 (66.5)	135 (58.7)
	Former	23 (10.1)	36 (15.7)
AJCC staging at study entry, n (%)	III	20 (8.8)	29 (12.6)
	IV	207 (91.2)	201 (87.4)
Distant metastatic site(s), n (%)	Liver	64 (28.2)	59 (25.7)
	Brain	1 (0.4)	4 (1.7)
≥3 metastatic sites, n (%)		183 (80.6)	164 (71.3)
Baseline LDH, n (%)	≤ULN	114 (50.2)	109 (47.4)
	>ULN	113 (49.8)	121 (52.6)
Choice of platinum $n (%)$	Cisplatin	47 (20.7)	49 (21.3)
Choice of platinum, n (%)	Carboplatin	180 (79.3)	181 (78.7)

Abbreviations: AJCC, American Joint Committee on Cancer; chemo, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ULN, upper limit of normal.





## **Overall Survival (OS)**



<sup>a</sup>One-sided p-value from stratified log-rank test; superiority threshold: 0.0211. Abbreviations: chemo, chemotherapy; CI, confidence interval; mo, months; OS, overall survival.




## OS Subgroup Analyses

Subgroup	Tislelizumab + chemo Event/total	Placebo + chemo Event/total	Hazard ratio (95% CI)ª	
Overall	164/227	191/230		0.75 (0.61, 0.93)
Age group				
<65 years	98/138	122/149		0.76 (0.58, 0.99)
≥65 years	66/89	69/81	— <b>—</b> —	0.73 (0.52, 1.02)
Sex				
Male	135/186	153/186		0.76 (0.60, 0.96)
Female	29/41	38/44		0.69 (0.42, 1.12)
ECOG performance status				
0	23/35	27/34	<b></b>	0.74 (0.42, 1.29)
1	141/192	164/196		0.75 (0.60, 0.94)
Smoking status				
Never	35/53	48/59	<b></b>	0.69 (0.44, 1.06)
Smoker	129/174	143/171		0.77 (0.60, 0.97)
AJCC staging at study entry				
III	11/20	21/29		0.62 (0.30, 1.29)
IV	153/207	170/201		0.74 (0.60, 0.93)
Liver metastases at baseline				
Yes	54/64	56/59		0.65 (0.44, 0.95)
No	110/163	135/171		0.75 (0.59, 0.97)
Brain metastasis				
No	163/226	187/226		0.75 (0.61, 0.93)
Baseline LDH				
≤ULN	78/114	88/109		0.72 (0.53, 0.98)
>ULN	86/113	103/121	<b></b>	0.80 (0.60, 1.06)
Choice of platinum				
Cisplatin	35/47	42/49		0.81 (0.51, 1.26)
Carboplatin	129/180	149/181		0.74 (0.58, 0.93)
	Cancer; chemo, chemotherapy; CI, confidence interva		0.0 1.0	2.0
ECOG, Eastern Cooperative Oncology Group; LDH, I	actate dehydrogenase; OS, overall survival; ULN, upp	er limit of normal. Tislelizi	umab + chemo Pla	acebo + chemo

Ying Cheng, Jilin Cancer Hospital, China



## Progression-free Survival (PFS)



Subgroup	Tislelizumab + chemo Event/total	Placebo + chemo Event/total	Hazard ratio (95% CI) <sup>b</sup>	
Overall	175/227	207/230		0.63 (0.51, 0.77)
Age group				, , ,
<65 years	105/138	138/149		0.58 (0.45, 0.76)
≥65 years	70/89	69/81		0.74 (0.53, 1.05)
Sex				
Male	143/186	165/186		0.69 (0.55, 0.87)
Female	32/41	42/44		0.38 (0.23, 0.63)
ECOG performance status				
0	28/35	29/34		0.65 (0.39, 1.10)
1	147/192	178/196		0.63 (0.50, 0.79)
Smoking status			l l	
Never	41/53	55/59		0.50 (0.32, 0.77)
Smoker	134/174	152/171		0.67 (0.53, 0.85)
AJCC staging at study entry				
III	14/20	25/29		0.50 (0.25, 1.00)
IV	161/207	182/201		0.62 (0.50, 0.77)
Liver metastases at baseline				
Yes	51/64	56/59	<b></b>	0.70 (0.47, 1.03)
No	124/163	151/171		0.60 (0.47, 0.77)
Brain metastasis				
No	174/226	204/226		0.63 (0.51, 0.77)
Baseline LDH				
≤ULN	91/114	97/109		0.63 (0.47, 0.84)
>ULN	84/113	110/121		0.64 (0.48, 0.86)
Choice of platinum				
Cisplatin	38/47	43/49		0.75 (0.48, 1.18)
Carboplatin	137/180	164/181		0.60 (0.48, 0.76)
		0.0	0.5 1.0	1.5 2.0

Tislelizumab + chemo

Placebo + chemo


<sup>a</sup>One-sided p-value from stratified log-rank test. <sup>b</sup>Unstratified hazard ratios.

Abbreviations: AJCC, American Joint Committee on Cancer; chemo, chemotherapy; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; mo, months; PFS, progression-free survival; ULN, upper limit of normal.



# These these

## **Confirmed Antitumor Response**




Abbreviations: chemo, chemotherapy; CI, confidence interval; CR, complete response; DoR, duration of response; mo, months; NA, not assessable; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; RECIST v1.1, Response Evaluation Criteria In Solid Tumours version 1.1; SD, stable disease.





## Safety Summary

	Tislelizumab + chemo (n=227)	Placebo + chemo (n=229)
Tislelizumab/placebo cycles		
Mean	11.8	7.3
Median (range)	6.0 (1-59)	6.0 (1-48)
>16 cycles, n (%)	44 (19.4%)	10 (4.4%)
Chemotherapy cycles, median, n (range)	4 (1-4)	4 (1-4)
TEAEs, n (%)	226 (99.6)	228 (99.6)
Treatment-related <sup>a</sup>	226 (99.6)	228 (99.6)
Grade ≥3	201 (88.5)	206 (90.0)
Serious	94 (41.4)	69 (30.1)
Leading to discontinuation <sup>b</sup>	30 (13.2)	7 (3.1)
Leading to death <sup>c</sup>	14 (6.2)	4 (1.7)
Tislelizumab/placebo-related	7 (3.1)	0 (0.0)
Chemotherapy-related	6 (2.6)	0 (0.0)
Immune-mediated AEs, n (%)	87 (38.3)	41 (17.9)
Leading to death	1 (0.4)	0 (0.0)
Infusion-related reactions, n (%)	8 (3.5)	5 (2.2)



The most common immune-mediated AEs in the tislelizumab plus chemo arm were hypothyroidism (13.7%), rash (13.2%), hyperthyroidism (5.7%)

<sup>a</sup>Related to any study drug. <sup>b</sup>Led to discontinuation of any component. <sup>c</sup>Tislelizumab/placebo related AE leading to death were respiratory failure, thrombocytopenia, gastrointestinal hemorrhage, autoimmune myocarditis, cardiac failure acute, depressed level of consciousness, and death. **Abbreviations:** AE, adverse event; chemo, chemotherapy, TEAE, treatment-emergent adverse event; WBC, white blood cell.





## Conclusions

- RATIONALE-312 met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in OS with tislelizumab plus chemotherapy compared with placebo plus chemotherapy in 1L ES-SCLC
  - Median OS 15.5 vs 13.5 months (HR 0.75 [95% CI: 0.61, 0.92]; P=0.0035)
  - Survival benefit was consistently observed across all the pre-defined subgroups, accompanied by significant improvement in PFS, increase in ORR, and more durable responses compared with placebo plus chemotherapy
- Tislelizumab plus chemotherapy showed a manageable safety profile

The results from this study confirm that the PD-1 inhibitor tislelizumab, in combination with chemotherapy, can improve OS in ES-SCLC, adding supporting evidence for the use of PD-1 inhibitors in 1L treatment of ES-SCLC

Abbreviations: IL, first-line; CI, confidence intervals; ES-SCLC, extensive-stage small cell lung cancer; HR, hazard ratio; OS, overall survival; PD-1, programmed cell death protein 1; PFS, progression-free survival.



## Acknowledgments

We as authors would like to thank

- **PATIENTS AND THEIR FAMILIES** for their study participation
- Investigators and site personnel from 51 centres in China for their support during the trial conduct

### This study was sponsored by **BeiGene**, Ltd.

Medical writing support, under the direction of the authors, was provided by Gemma Walker, BSc, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd. Editorial support was provided by Elizabeth Hermans, PhD, of BeiGene, Ltd.

Please use this link to view a **PLS of the abstract**: <u>https://protect-eu.mimecast.com/s/VCdBCzVZuMO31Qku4dxhY?domain=epg-digital.com</u> **Note:** Copies of this PLS obtained through this link are for personal use only and may not be reproduced without written permission of the authors.